Clinical trial

Prevention of Osteoporosis in Men With Prostate Cancer

NCT00048841

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record alendronate Normalized identity: alendronateView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Prevention of Osteoporosis in Men With Prostate Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2002-05-01

PhasePHASE3

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Osteoporosisverified · MONDO: osteoporosis

Hypogonadismverified · MONDO: hypogonadism

Interventions

alendronateDRUG · verified · RxNorm: alendronate

Sponsors & collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)lead sponsor

Mapped research locations

PittsburghPennsylvania, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00048841 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.